Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Inhaled vs Chewable Aspirin in Lung Disease
NCT05625347Phase 1Terminated
- Sponsor
- Vectura
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aspirin in myocardial infarction (MI) (2 arms), sponsored by Vectura. Primary endpoints: Peak plasma concentration of ASA, Area under the ASA plasma concentration versus time curve (AUC0-inf) and 1 more. Started Mar 2023; status: terminated.
02
Drugs
aspirin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT05625347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625347.